What is Sickle Cell Anemia?
Sickle cell anaemia (SCA) is the world’s most common genetic disorder, affecting red blood cells that become rigid and sickle-shaped instead of flexible and round. This causes severe complications including painful crises, blocked blood flow, organ damage, and reduced life expectancy, particularly devastating for children and adolescents.
Why Memantine?
Memantine has been used to treat Alzheimer’s disease for about 20 years, making it no longer patent-protected. This FDA-approved drug is now being repurposed for sickle cell disease as an affordable alternative, especially valuable for resource-limited regions in Africa and India where the disease burden is highest.
Current treatments face limitations:
∙ Hydroxyurea isn’t well-tolerated by all patients
∙ Bone marrow transplants require suitable donors
∙ Gene therapies cost hundreds of thousands of dollars
How Does Memantine Work?
Memantine blocks N-methyl D-aspartate receptors (NMDAR), which allow calcium ions to enter the cell when activated. In sickle cell disease, these receptors are overactive in red blood cells. By blocking them, memantine stabilizes red blood cell membranes, reduces sickling, and may also help relieve pain and inflammation.
Clinical Trial Results (MeMAGEN Study)
Published in HemaSphere (January 2025), the Phase IIa/IIb trial included 17 study participants who received age-appropriate doses of memantine for 12 months.
Key findings:
Treatment was well tolerated, and more than 25 laboratory parameters confirmed the drug’s safety
Both the number and duration of hospitalisations decreased significantly
Children in particular experienced fewer painful flare-ups
No serious side effects or discontinuations of the study due to the therapy itself were observed
Improved cognitive function, including processing speed, working memory, and attention
Important Note on Study Design
All patients involved in the study continued their existing hydroxyurea therapy, as discontinuing it would have been unethical. Therefore, memantine’s effects should be viewed as complementary to hydroxyurea, not a replacement. Future studies will examine memantine in patients not receiving hydroxyurea.
Why This Matters
As an off-patent, easy-to-store medication, memantine represents a cost-effective supportive therapy that could significantly reduce healthcare burden in developing countries. Researchers are now planning larger trials to systematically evaluate combination therapies and confirm these promising early results.
Final Thoughts
While not a cure, memantine shows potential as a safe, affordable addition to sickle cell treatment, reducing hospitalisations, painful episodes, and improving patients’ quality of life. The research team at the University of Zurich continues investigating this repurposed drug’s full therapeutic potential.
MBH/AB